Atlanta, GA -The factor Xa inhibitor antithrombotic fondaparinux reduced mortality and reinfarction without increasing bleeding, compared with usual care (unfractionated heparin [UFH] or no ...
The combined use of anticoagulants, antiplatelet agents, and invasive coronary procedures reduces ischemic coronary events but also increases bleeding in patients with acute coronary syndromes. We ...
A study has revealed that fondaparinux, a synthetic inhibitor of coagulation factor Xa, is a promising treatment option for patients with acute coronary syndromes. Mehta et al. performed a combined ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback